Résilience - COVID-19 - Résilience - Coronavirus disease 2019

Identification of early biomarkers of the response to corticosteroid therapy in COVID-19 patients. – CortiCoV

Submission summary

SARS-CoV-2 is the human coronavirus that caused the pandemic that began in Wuhan, China at the end of 2019. This virus is the source of a contagious respiratory pathology known as COVID-19. The study of the first patients infected with severe forms of COVID-19 revealed an intense inflammatory response of the host, called cytokine storm characterized by an increased levels of cytokines such as IL-1beta whose secretion is controlled by protein complexes called inflammasomes. We have developed a test to predict the course of the disease based on the analysis of the activation state of the NLRP3 inflammasome of myeloid cells in the blood. Here we propose to use this assay to determine if these parameters can allow to differentiate good and bad responders to the corticosteroid therapy and to use the analysis of myeloid cells of these COVID-19 patients to identify new biomarkers

Project coordination

Laurent BOYER (CENTRE MEDITERRANEEN DE MEDECINE MOLECULAIRE)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

C3M CENTRE MEDITERRANEEN DE MEDECINE MOLECULAIRE

Help of the ANR 50,760 euros
Beginning and duration of the scientific project: June 2021 - 12 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter